Chronic Eosinophilic Leukemia

Updated: July 20, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

imatinib

400 mg orally daily for patients with HES/CEL  
100 mg orally given daily for patients with HES/CEL with demonstrated FIP1L1-PDGFR alpha fusion kinase  
An increased dose of 100 mg to 400 mg can be considered for those patients if no adverse drug reactions are seen and if assessments demonstrate an insufficient response to therapy  
 continue the treatment until there is no progressive disease or unacceptable toxicity occurs 

Future Trends